Oncology Meets Immunology: The Cancer-Immunity CycleDaniel S. Chen(Stanford University), Ira Mellman(University of California, San Francisco)ImmunityJuly 1, 201310.1016/j.immuni.2013.07.012Cited by 6,879Open AccessFull TextSaveCiteExport RISWatch citationsAbstractRelated PapersPhase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R. Brahmer, Charles G. Drake, Ira Wollner et al.|Journal of Clinical Oncology|2010|2.9kThe PD‐1 pathway in tolerance and autoimmunityLoise M. Francisco, Peter T. Sage, Arlene H. Sharpe|Immunological Reviews|2010|2.3kTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L. Topalian, Charles G. Drake, Drew M. Pardoll|Current Opinion in Immunology|2012|1.3kCommensal bacteria at the interface of host metabolism and the immune systemJonathan R. Brestoff, David Artis|Nature Immunology|2013|945The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic SignaturesJérôme Galon, Helen K. Angell, Davide Bedognetti et al.|Immunity|2013|868